GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cyclacel Pharmaceuticals
Cyclacel is a biotech company developing cancer treatments. Its stock price is volatile and dependent on clinical trial results. The chart reflects investor confidence in the potential of its oncology drugs.
Share prices of companies in the market segment - General oncology therapy
Cyclacel Pharmaceuticals is a biopharmaceutical company developing targeted therapies for the treatment of cancer and other serious diseases. We have classified it in the "General Oncology" category. The chart below shows how investors value clinical-stage companies with a broad pipeline.
Broad Market Index - GURU.Markets
Cyclacel Pharmaceuticals is a biotech company developing targeted drugs for the treatment of cancer and other serious diseases. Its scientific advancements make it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Cyclacel shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
CYCC - Daily change in the company's share price Cyclacel Pharmaceuticals
For Cyclacel Pharmaceuticals, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - General oncology therapy
Cyclacel Pharmaceuticals is a biopharmaceutical company developing targeted therapies for the treatment of cancer and other serious diseases. Oncology is a volatile sector. The chart below reflects the average fluctuations in this industry, providing context for evaluating CYCC stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Cyclacel is a biotech company developing drugs to treat cancer. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals' year-to-date performance is a story of targeted cancer drug development. Its 12-month market cap is entirely dependent on clinical trial data. Positive results for its kinase inhibitors could offer new hope for patients with difficult-to-treat cancers.
Annual dynamics of market capitalization of the market segment - General oncology therapy
Cyclacel, a clinical-stage biotech company, develops drugs for the treatment of cancer. Its stock price is entirely dependent on the results of clinical trials. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector compared to big pharma.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cyclacel Pharmaceuticals is a biotech company whose value is locked into its cancer drug pipeline. Its shares move in sync with clinical trial news. A sharp rise or fall amid a calm market is clear evidence that investors are betting on science.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cyclacel Pharmaceuticals
Cyclacel is a clinical-stage oncology company. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its cell cycle inhibitors are binary events, causing sharp fluctuations.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
Cyclacel Pharmaceuticals is an oncology company developing drugs that target the cell division cycle of cancer cells. This is a fundamental approach to treatment. The dynamics of the biotech sector, as shown in the graph, reflect the hopes and risks associated with drug development. Cyclacel's story is a long and arduous journey from scientific hypothesis to potential regulatory approval.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted therapies for the treatment of cancer. The company's future depends on the success of its clinical trials. The broader market chart serves as just a backdrop to illustrate how scientific news and the potential of its platform have driven its stock movements completely independent of overall sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is a clinical-stage oncology company. Its weekly stock price, like that of other biotech companies, is entirely dependent on news about the progress of clinical trials of its targeted drugs, which can cause sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
Cyclacel Pharmaceuticals develops targeted drugs for cancer treatment. Like many biotech companies, its shares react sensitively to the publication of research data. This chart is your tool for analysis: is Cyclacel's weekly stock price driven by the progress of its drugs or by overall sentiment in the oncology sector?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cyclacel is a clinical-stage oncology company. Its shares are buoyed by anticipation of trial results. The chart clearly demonstrates how its performance is driven by scientific news rather than general market trends, creating its own unique path.
Market capitalization of the company, segment and market as a whole
CYCC - Market capitalization of the company Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals' market capitalization chart represents a clinical-stage biotech company focused on cancer treatment. Its low valuation and high volatility reflect the company's long history and the risks associated with drug development. It's a high-risk bet that one of its drug candidates will finally succeed.
CYCC - Share of the company's market capitalization Cyclacel Pharmaceuticals within the market segment - General oncology therapy
Cyclacel Pharmaceuticals is a biotech company focused on developing cancer drugs. Its market share in the pharmaceutical sector is extremely small, which is typical for companies in the clinical trial stage. Its market capitalization dynamics directly reflect news about its drug trials and investor confidence in their success.
Market capitalization of the market segment - General oncology therapy
Here's a chart showing the market capitalization of the biotech sector. Cyclacel Pharmaceuticals is a company focused on developing a new generation of cancer drugs targeting the cell cycle. Its market history is marked by a long and complex journey through clinical trials. The performance of such companies depends entirely on scientific data and investor confidence in their approach.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cyclacel is an oncology company developing drugs that target the cell division cycle of cancer cells. Its market capitalization is a bet on this fundamental approach. The chart below shows the economic weight of companies working in this field.
Book value capitalization of the company, segment and market as a whole
CYCC - Book value capitalization of the company Cyclacel Pharmaceuticals
Cyclacel's book value is derived from its intellectual property in its portfolio of cell cycle inhibitor drugs for cancer treatment. The chart tells the story of a biotech company that has invested its capital in clinical research for years, building an intangible foundation in hopes of a scientific breakthrough.
CYCC - Share of the company's book capitalization Cyclacel Pharmaceuticals within the market segment - General oncology therapy
Cyclacel Pharmaceuticals develops targeted cancer therapies. The chart shows its share of actual R&D assets. These include its laboratories and clinical programs, which provide the foundation for developing next-generation anticancer drugs.
Market segment balance sheet capitalization - General oncology therapy
Cyclacel Pharmaceuticals is a biopharmaceutical company specializing in oncology. They focus on clinical research rather than manufacturing. A book value chart shows their modest R&D base, as their main asset is intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Cyclacel's assets include laboratories and R&D centers for developing small molecules targeting the cell cycle for cancer treatment. The chart shows how the company built its scientific and material foundation to advance its clinical candidates.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cyclacel Pharmaceuticals
For Cyclacel Pharmaceuticals, a cancer drug developer, the book value is minimal. The chart is a pure indicator of sentiment surrounding its clinical trials. You'll see how the market valuation, based solely on hopes for a scientific breakthrough, rises and falls on news, living a life entirely separate from the company's assets.
Market to book capitalization ratio in a market segment - General oncology therapy
Cyclacel Pharmaceuticals is a clinical-stage biotech company focused on developing cancer treatments. Its valuation depends almost entirely on the results of clinical trials and the future potential of its drugs. The chart reflects the high risk and potential reward that investors are pricing in.
Market to book capitalization ratio for the market as a whole
Cyclacel Pharmaceuticals is a biotech company focused on cancer treatment. Its market capitalization is almost entirely dependent on clinical trial results. This chart shows the wide gap typical for the sector between the market valuation based on the future potential of its drugs and the current value of its tangible assets.
Debts of the company, segment and market as a whole
CYCC - Company debts Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is a clinical-stage biotech company focused on developing targeted cancer therapies. This chart illustrates its long history in R&D. The company funds its clinical trials through periodic equity raisings, and its survival depends on the success of these studies.
Market segment debts - General oncology therapy
Cyclacel Pharmaceuticals is a clinical-stage biotech company focused on developing targeted therapies for cancer treatment. Its survival and success depend entirely on its ability to raise capital to fund research. This chart clearly demonstrates the high financial risk inherent in this industry.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is a clinical-stage oncology company. This chart shows its financial structure. For a biotech company whose future depends on clinical trial results, debt is a huge risk. Research failure could make it impossible to sustain and lead to bankruptcy.
Market segment debt to market segment book capitalization - General oncology therapy
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing cancer treatments. This chart shows the debt burden in the biotech sector, a key indicator of the company's ability to fund its expensive research and development in this highly competitive field.
Debt to book value of all companies in the market
Cyclacel Pharmaceuticals is a clinical-stage oncology company developing targeted therapies. Its survival is entirely dependent on external funding. This chart of total market debt serves as a barometer of the investment climate, showing how easy or difficult it is for companies like Cyclacel to raise funds to continue research.
P/E of the company, segment and market as a whole
P/E - Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is a biotech company developing targeted drugs for the treatment of cancer and other serious diseases. This chart reflects the high risks associated with early-stage clinical development. Its dynamics are entirely dependent on trial results and are not linked to current financial performance.
P/E of the market segment - General oncology therapy
Cyclacel Pharmaceuticals is a clinical-stage biotech company focused on developing targeted therapies for cancer and other serious diseases. Its approach is based on cell cycle inhibition. This chart shows the average valuation for the oncology therapeutics sector, reflecting how investors assess the risks and potential of smaller biotech companies.
P/E of the market as a whole
Cyclacel Pharmaceuticals is a biopharmaceutical company developing cancer treatments. Its valuation, like that of other companies at this stage, is unrelated to the general economic cycles depicted by this chart. The company's value is determined solely by the success or failure of its scientific research and clinical trial data.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is a biotech company developing targeted cancer therapies that target cell cycle regulation. This graph reflects market expectations for the success of its clinical programs. Future revenue is entirely dependent on the results of trials and approval of its drug candidates.
%20P%2FE%20Cyclacel%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cyclacel-Pharmaceuticals&v=1772643325717 "Chart of the company's future (projected) P/E Cyclacel Pharmaceuticals")
Future (projected) P/E of the market segment - General oncology therapy
Cyclacel Pharmaceuticals is a biopharmaceutical company developing targeted therapies for the treatment of cancer and other serious diseases. The chart reflects average expectations for the oncology segment. CYCC's position relative to this benchmark reflects investor assessment of its scientific approach to cell cycle inhibition and progress in clinical trials.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772643325729 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for the treatment of cancer and other serious diseases. Its approach is based on cell cycle inhibition. This chart of overall market expectations illustrates investor appetite for the risk required to fund lengthy and expensive clinical trials in oncology.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772643325731 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is a clinical-stage biotechnology company focused on developing targeted therapies for cancer treatment. Its financial schedule is based on research and clinical trial expenses. Potential profitability is entirely dependent on the success of its candidate cancer drugs.
Profit of companies in the market segment - General oncology therapy
Cyclacel Pharmaceuticals is a biopharmaceutical company developing targeted drugs for the treatment of cancer and other serious diseases by interfering with the cell cycle. This chart shows the overall profitability of the oncology sector. It reflects the willingness of investors to fund breakthrough but risky developments and the overall progress of the sector in the fight against cancer.
Overall market profit
Cyclacel Pharmaceuticals is a biotech company developing targeted drugs for cancer treatment. Its future depends on the success of clinical trials. The overall market situation, as shown in this chart, doesn't affect demand for the drug but is critical for raising funds, as investors are more inclined to invest in risky projects during periods of growth.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is a biopharmaceutical company developing cancer treatments based on cell cycle inhibitors. Future profits are entirely dependent on the success of clinical trials. This chart reflects analysts' speculative expectations regarding the potential of its scientific approaches in oncology.
%20profit%20of%20the%20company%20Cyclacel%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cyclacel-Pharmaceuticals&v=1772643325774 "Graph of future (projected) profit of the company Cyclacel Pharmaceuticals")
Future (predicted) profit of companies in the market segment - General oncology therapy
Cyclacel Pharmaceuticals is a biotech company developing targeted cancer therapies that target the cell cycle. Its success depends on clinical trial results and partnerships with major pharmaceutical companies. This chart shows forecasts for the entire biotech sector, providing context for assessing Cyclacel's potential and risks in the competitive oncology field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772643325789 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
Cyclacel Pharmaceuticals is a biotechnology company developing cancer treatments. Its value and future are determined solely by the results of clinical trials and the potential of its research. The overall macroeconomic indicators presented in this chart are irrelevant.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772643325796 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is a clinical-stage biotech company focused on cancer treatment. Without sales revenue, its market value, as shown in this chart, is based entirely on the potential of its drug candidates. The price action is a direct reaction from investors to news of clinical trial results.
P/S market segment - General oncology therapy
Cyclacel Pharmaceuticals is a biopharmaceutical company developing targeted therapies for the treatment of cancer and other serious diseases. Future revenue depends on the success of its clinical programs. This chart for the oncology sector compares investor expectations for Cyclacel's scientific approach with those of other companies working in this field.
P/S of the market as a whole
Cyclacel Pharmaceuticals is a clinical-stage biotech company developing targeted therapies for the treatment of cancer and other serious diseases. Its approach is based on cell cycle inhibition. This market revenue valuation chart helps understand how investors view the company's scientific platform and its potential in oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is a clinical-stage biotechnology company focused on developing targeted therapies for the treatment of cancer and other serious diseases. This chart shows how the market perceives the future commercial potential of its developments. It reflects investor confidence in the company's scientific platform and the success of its clinical programs.
%20P%2FS%20Cyclacel%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cyclacel-Pharmaceuticals&v=1772643325845 "The graph of the company's future (projected) P/S Cyclacel Pharmaceuticals")
Future (projected) P/S of the market segment - General oncology therapy
Cyclacel Pharmaceuticals is a clinical-stage biotechnology company developing targeted cancer therapies that target cell cycle mechanisms. The company's valuation, like many of its peers, depends entirely on the clinical trial results of its candidates and investor confidence in the scientific potential of its developments.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772643325846 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of oncology. Its prospects depend on the success of its research. In the context of the overall revenue projections shown in the chart, Cyclacel represents a venture investment in the future of oncology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772643325853 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is a clinical-stage biotechnology company specializing in the development of cancer treatments. The company currently has no commercial products and, therefore, no sales revenue. Any revenue shown in the chart likely comes from licensing or partnership agreements.
Sales of companies in the market segment - General oncology therapy
Cyclacel Pharmaceuticals (CYCC) is a biopharmaceutical company focused on developing targeted therapies for the treatment of cancer and other serious diseases. Its approach is based on cell cycle control, a metric that reflects revenue in the oncology sector. Cyclacel's drugs target fundamental tumor growth mechanisms, which could be effective across a wide range of cancer types.
Overall market sales
Cyclacel Pharmaceuticals is a biotech company developing cancer treatments. Its market capitalization depends on progress in clinical trials. This pattern of overall economic activity influences investors' overall risk appetite. During periods of growth and market optimism, biotech companies like Cyclacel find it easier to attract the funding they need for research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is a biotechnology company developing targeted therapies for the treatment of cancer and other serious diseases. Its future revenue depends on the success of clinical trials and partnerships. This chart reflects analyst expectations, which are essentially an assessment of the scientific potential and commercial prospects of its oncology developments.
%20sales%20of%20the%20company%20Cyclacel%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cyclacel-Pharmaceuticals&v=1772643325903 "Schedule of future (projected) sales of the company Cyclacel Pharmaceuticals")
Future (projected) sales of companies in the market segment - General oncology therapy
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing cancer treatments. This forecast chart reflects the potential future revenue from their pipeline of candidates. It represents analysts' views on the commercial prospects of their cancer treatment approaches.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772643325910 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
Cyclacel Pharmaceuticals is a biotech company developing targeted therapies for cancer treatment. Its strategy is based on a deep understanding of the cell cycle. This chart reflects the overall investment climate, which influences funding, but for Cyclacel, the key factors are progress in its clinical trials and the potential of its drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772643325917 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is a clinical-stage biotechnology company developing drugs for the treatment of cancer and other serious diseases. Its financial performance reflects its high R&D expenditures. The chart shows its current profitability, which represents an investment in the development of next-generation anticancer drugs.
Market segment marginality - General oncology therapy
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing cancer drugs based on cell cycle inhibitors. This chart reflects its operating expenses. Future profitability is entirely dependent on the success of its clinical programs and potential partnerships with major pharmaceutical companies.
Market marginality as a whole
Cyclacel Pharmaceuticals is a biotech company developing targeted drugs for cancer treatment. It is currently in clinical trials. This total return chart reflects investors' willingness to finance risky projects. During periods of economic growth, capital inflows into the biotech sector increase, which is important for such companies.
Employees in the company, segment and market as a whole
Number of employees in the company Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cancer treatment. As a research-based organization, it operates with a small team. This graphic shows the small but highly qualified staff of scientists advancing its developments through clinical trials.
Share of the company's employees Cyclacel Pharmaceuticals within the market segment - General oncology therapy
Cyclacel Pharmaceuticals is a clinical-stage biotechnology company focused on cancer drug development. Its team consists primarily of scientists and clinical trial specialists. This schedule reflects its business model: a small but highly qualified staff dedicates all resources to research and development.
Number of employees in the market segment - General oncology therapy
Cyclacel Pharmaceuticals develops targeted drugs for the treatment of cancer and other serious diseases. This chart, showing the workload in oncology therapy, demonstrates the scale and competition in this field. For Cyclacel, which focuses on cell cycle inhibitors, the growing number of researchers means both accelerating research and the need to prove the superiority of its approach.
Number of employees in the market as a whole
Cyclacel Pharmaceuticals is a biotech company specializing in the development of innovative cancer treatments. Its future depends on successful clinical trials and raising capital. The overall economic situation, reflected in this employment graph, influences investor willingness to finance long-term and risky biotech projects.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cyclacel Pharmaceuticals (CYCC)
Cyclacel Pharmaceuticals (CYCC) is a biotech company focused on cancer treatment. This chart is a sign of hope for biotech investors. The company's market value in the early stages is almost entirely based on its intellectual property and clinical development potential. The per-employee value is high because it is not tied to physical manufacturing.
%20of%20the%20company%20Cyclacel%20Pharmaceuticals%20(CYCC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cyclacel-Pharmaceuticals-CYCC&v=1772643326104 "Chart of market capitalization per employee (in thousands of dollars) of the company Cyclacel Pharmaceuticals (CYCC)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
Cyclacel Pharmaceuticals is a biotech company specializing in cancer treatments. Its market capitalization is based on the potential of its clinical pipeline. This metric demonstrates the future value the market places on the work of each scientist who can advance the development of a new drug.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772643326106 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Cyclacel Pharmaceuticals is a clinical-stage biotech company focused on developing cancer treatments. Its value depends almost entirely on the success of clinical trials. This chart for Cyclacel is a prime example of a biotech company where the market value per employee can be colossal, reflecting the hope of developing a new drug.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772643326110 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cyclacel Pharmaceuticals (CYCC)
Cyclacel Pharmaceuticals is a clinical-stage biotech company focused on oncology. The company is unprofitable. This graph will show a negative value—the loss per employee. This reflects the amount of capital the company is burning through on clinical research in the hopes of developing a new cancer drug.
%20Chart%20Cyclacel%20Pharmaceuticals%20(CYCC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cyclacel-Pharmaceuticals-CYCC&v=1772643326132 "Company Profit Per Employee (in thousands of dollars) Chart Cyclacel Pharmaceuticals (CYCC)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
Cyclacel Pharmaceuticals is a biotech company specializing in cancer drug development. For such companies, the productivity of their research teams is a key asset during clinical trials. This chart shows the financial return per employee, which helps investors evaluate the efficiency of capital utilization during the development of a new drug.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772643326162 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Cyclacel Pharmaceuticals is a biotech company focused on developing targeted drugs for the treatment of cancer, particularly leukemia. This is pure R&D. This chart shows the average profitability of one employee in the economy. It provides investors with context: the biotech sector operates in an all-or-nothing paradigm, where the return on personnel (scientists) can be colossal if successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772643326214 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cyclacel Pharmaceuticals (CYCC)
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing cancer treatments. Because it has no commercial products yet, revenue per employee is minimal or nonexistent. This chart clearly illustrates the R&D phase, where all value is generated through oncology research and development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cyclacel-Pharmaceuticals-CYCC&v=1772643326276 "Sales chart per company employee Cyclacel Pharmaceuticals (CYCC)")
Sales per employee in the market segment - General oncology therapy
Cyclacel Pharmaceuticals (CYCC) is a biotech company specializing in the development of targeted cancer therapies that target the cell cycle. This chart shows the average revenue per employee in the sector. It is important for assessing R&D efficiency and personnel structure compared to other oncology biotechs.
Sales per employee for the market as a whole
Cyclacel Pharmaceuticals (CYCC) is a clinical-stage biotechnology company focused on developing targeted therapies for cancer treatment. The company has a long history of R&D. This R&D metric, close to zero (as there are no commercial products), reflects ongoing operating expenses for its scientific staff, who continue their research in search of breakthroughs.
Short shares by company, segment and market as a whole
Shares shorted by company Cyclacel Pharmaceuticals (CYCC)
Cyclacel (CYCC) is a clinical-stage biotech company that has been developing cancer treatments for years. This chart shows short interest. The high short interest reflects investors' chronic lack of confidence in the company's pipeline after a string of past failures and the high risk of capital dilution (additional share issues) to fund R&D. (348)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cyclacel-Pharmaceuticals-CYCC&v=1772643326335 "Short Shares Chart for the Company Cyclacel Pharmaceuticals (CYCC)")
Shares shorted by market segment - General oncology therapy
Cyclacel (CYCC) is a biopharmaceutical company developing targeted cancer drugs, focusing on cell cycle inhibitors. The chart below shows the aggregate short position in the oncology biotech sector. It reflects investor skepticism about the success of risky clinical trials in this area.
Shares shorted by the overall market
Cyclacel is a biotech company focused on oncology. It's a classic R&D story. This chart measures the overall level of fear in the market. When it's high, investors are unwilling to fund multi-year clinical trials. They see "another unprofitable company" and sell it, fearing the "cash" will run out before success.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cyclacel Pharmaceuticals (CYCC)
Cyclacel Pharmaceuticals (CYCC) is a biotech company developing targeted cancer drugs, focusing on cell cycle inhibitors. This is a high-risk area. This chart measures the strength of speculative moves. It shows when the stock is "overheated" (above 70) due to early data or "oversold" (below 30) due to a lack of news.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cyclacel-Pharmaceuticals-CYCC&v=1772643326436 "RSI 14 indicator chart for the company's stock Cyclacel Pharmaceuticals (CYCC)")
RSI 14 Market Segment - General oncology therapy
Cyclacel Pharmaceuticals is a biotech company specializing in the development of drugs (kinase inhibitors) for the treatment of cancer, particularly leukemia and lymphoma. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire speculative segment is oversold.
RSI 14 for the overall market
For Cyclacel Pharmaceuticals, a biotech company in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CYCC (Cyclacel Pharmaceuticals)
Cyclacel is a clinical-stage biopharmaceutical company focused on developing cell cycle inhibitors, a new class of targeted therapies for cancer treatment. This chart shows the speculative average price target from analysts, which is almost entirely dependent on their confidence in the company's R&D pipeline and clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CYCC-Cyclacel-Pharmaceuticals&v=1772643326479 "A chart showing analyst consensus forecasts for the expected stock price. CYCC (Cyclacel Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price CYCC (Cyclacel Pharmaceuticals)
Cyclacel is a biotech company developing cancer treatments (inhibitors) that target the cell division mechanism. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their "venture capital" valuation of the company's R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CYCC-Cyclacel-Pharmaceuticals&v=1772643326495 "A chart showing the difference between the consensus forecast and the actual stock price. CYCC (Cyclacel Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
Cyclacel is a clinical-stage biotech developing small-molecule drugs (tablets) for cancer treatment. This is a risky R&D venture. This chart shows analysts' overall expectations for the entire oncology sector. It reflects whether experts believe the R&D pipeline is successful or whether they consider the industry overheated.
Analysts' consensus forecast for the overall market share price
Cyclacel Pharmaceuticals is a biotech company specializing in developing cancer treatments that target the cell cycle (cell division). This chart reflects the overall market "risk appetite." For Cyclacel, a high-risk clinical-stage company, overall market optimism (risk appetite) is critical to attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cyclacel Pharmaceuticals
Cyclacel is a biotech veteran that has been searching (and failing) for decades for a breakthrough in oncology. Their R&D pipeline (CDK inhibitors) aims to stop the cancer cell cycle. This chart is a summary indicator of their perpetual R&D. It reflects not profit, but their (constant) cash burn and the market's (low) faith in their (very risky) pipeline.
AKIMA Market Segment Index - General oncology therapy
Cyclacel Pharmaceuticals is an oncology biotech. They develop drugs (kinase inhibitors) that aim to stop the uncontrolled division of cancer cells. This is a fundamental approach to cancer treatment. This chart compares their composite index to the sector, showing how their R&D strategy compares to other biotechs.
The AKIM Index for the overall market
Cyclacel Pharmaceuticals is a biopharmaceutical company developing drugs that regulate the cell cycle in cancer and leukemia. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story compares to overall economic trends.
